Literature DB >> 33685471

Philadelphia chromosome positive chronic myeloid leukemia with 5q deletion at diagnosis.

Ahmed Maseh Haidary1, Zeeshan Ansar Ahmed2, Jamshid Abdul-Ghafar3, Soma Rahmani3, Sarah Noor4, Farahnaz Erfani3, Maryam Ahmad3, Naeem Lakanwall3, Haider Ali Malakzai3, Abdul Sami Ibrahimkhil3, Esmatullah Esmat3, Mujtaba Haidari3, Nimattullah Yousufzai3, Samuel Sharif3, Abdul Hadi Saqib3.   

Abstract

BACKGROUND: Although, molecular genetic analyses became more and more important to guide therapy decisions in leukemia, banding cytogenetic analysis has retained its vital role in diagnosis and monitoring of chronic myeloid leukemia (CML), by quick and easy enabling identification of pathognomonic Philadelphia chromosome (Ph). CASE
PRESENTATION: A 45 year old female presented with characteristic hematological features of CML in chronic phase; cytogenetic studies revealed the presence of the typical Ph and a deletion of almost entire long arm of a chromosome 5.
CONCLUSION: 5q deletions have rarely been reported in CML. Those seen yet were either associated with tyrosine kinase inhibitor therapy or detected post allogeneic stem cell transplantation. To our knowledge, this is the first case of Ph positive CML accompanied by a 5q deletion.

Entities:  

Keywords:  5q deletion; Chronic myelogenous leukemia (CML); Philadelphia chromosome (Ph)

Year:  2021        PMID: 33685471     DOI: 10.1186/s13039-021-00539-0

Source DB:  PubMed          Journal:  Mol Cytogenet        ISSN: 1755-8166            Impact factor:   2.009


  2 in total

1.  FISH versus real-time quantitative PCR for monitoring of minimal residual disease in chronic myeloid leukaemia patients on tyrosine kinase inhibitor therapy.

Authors:  A M Haidary; R Z Azma; A Ithnin; H Alauddin; N R Tumian; A M Tamil; N F A Razak; S H Abu Amis; N M Zin; S Shuib
Journal:  Malays J Pathol       Date:  2019-08       Impact factor: 0.656

2.  5q- in a case of chronic myelogenous leukemia relapsed after allogeneic bone marrow transplantation.

Authors:  D Soligo; L Romitti; V Bertolli; A Della Volpe; C Annaloro; G Lambertenghi Deliliers
Journal:  Haematologica       Date:  1995 Sep-Oct       Impact factor: 9.941

  2 in total
  3 in total

Review 1.  The Relevance of Aurora Kinase Inhibition in Hematological Malignancies.

Authors:  Caio Bezerra Machado; Emerson Lucena DA Silva; Beatriz Maria Dias Nogueira; Jean Breno Silveira DA Silva; Manoel Odorico DE Moraes Filho; Raquel Carvalho Montenegro; Maria Elisabete Amaral DE Moraes; Caroline Aquino Moreira-Nunes
Journal:  Cancer Diagn Progn       Date:  2021-07-03

2.  Acute lymphoblastic leukemia with clonal evolution due to delay in chemotherapy: A report of a case.

Authors:  Ahmed Maseh Haidary; Ramin Saadaat; Jamshid Abdul-Ghafar; Soma Rahmani; Sarah Noor; Sahar Noor; Najla Nasir; Maryam Ahmad; Ahmad Shekib Zahier; Rohullah Zahier; Haider Ali Malakzai; Abdul Sami Ibrahimkhil; Samuel Sharif; Tawab Baryali; Inamullah Mohib; Abdul Hadi Saqib; Raja Zahratul Azma
Journal:  EJHaem       Date:  2022-06-07

3.  Anticancer potential of mebendazole against chronic myeloid leukemia: in silico and in vitro studies revealed new insights about the mechanism of action.

Authors:  Julio Paulino Daniel; Felipe Pantoja Mesquita; Emerson Lucena Da Silva; Pedro Filho Noronha de Souza; Luina Benevides Lima; Lais Lacerda Brasil de Oliveira; Maria Elisabete Amaral de Moraes; Caroline de Fátima Aquino Moreira-Nunes; Rommel Mario Rodríguez Burbano; Geancarlo Zanatta; Raquel Carvalho Montenegro
Journal:  Front Pharmacol       Date:  2022-08-25       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.